文献速递支持与姑息治疗

晚期癌症谵妄激越症状的按比例镇静随机临床试验

Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2025-01-01

这项多中心随机临床试验纳入111例晚期癌症伴持续性躁动或激越的姑息治疗患者,比较定期静脉氟哌啶醇、劳拉西泮、两药联合与安慰剂的效果。主要终点为24小时内RASS评分变化,劳拉西泮组和联合组RASS评分显著低于氟哌啶醇组,而氟哌啶醇与安慰剂无差异;联合组和劳拉西泮组抢救药物使用更少。

要点

  • 劳拉西泮组RASS评分较氟哌啶醇组显著降低,平均差-2.1(95%CI -3.4至-0.9,P<.001)。
  • 联合组RASS评分较氟哌啶醇组显著降低,平均差-2.0(95%CI -3.2至-0.8,P=.002)。
  • 氟哌啶醇与安慰剂组RASS评分无差异(平均差-0.5,95%CI -1.7至0.7,P=.42)。

核心结论

  • 在晚期癌症伴谵妄和持续性躁动/激越的姑息治疗患者中,主动使用定期镇静剂尤其是含劳拉西泮方案可能减轻症状。

研究设计与样本

  • 多中心随机临床试验,在台湾和美国3个急性姑息治疗单元开展,245例合格患者中111例入组,75例接受盲法治疗。
  • 参与者按1:1:1:1随机分配至定期静脉氟哌啶醇、劳拉西泮、氟哌啶醇联合劳拉西泮或安慰剂组,每4小时给药直至出院、死亡或退出研究。
  • 研究期为2019年7月16日至2023年6月8日,给药后随访30天。

主要发现

  • 主要终点在72例患者中评估,平均(SD)年龄64(12)岁,42例男性(58%),中位(IQR)MDAS评分24(18-29)。
  • 劳拉西泮组RASS评分显著低于氟哌啶醇组(平均差-2.1,95%CI -3.4至-0.9,P<.001)。
  • 联合组RASS评分显著低于氟哌啶醇组(平均差-2.0,95%CI -3.2至-0.8,P=.002)。
  • 氟哌啶醇与安慰剂组无差异(平均差-0.5,95%CI -1.7至0.7,P=.42),联合组与劳拉西泮组无差异(平均差0.2,95%CI -1.1至1.4,P=.79)。
  • 联合组和劳拉西泮组因突破性躁动/激越需抢救药物者少于氟哌啶醇和安慰剂组(分别为32%、37%、56%、83%,P=.006)。

临床怎么用

  • 对于晚期癌症伴谵妄和持续性躁动/激越的姑息治疗患者,可考虑定期使用劳拉西泮为基础的镇静方案。
  • 氟哌啶醇单药在控制持续性躁动/激越方面未优于安慰剂,应审慎评估其使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Neuroleptic and benzodiazepine medications are often considered for patients with persistent agitated delirium in the last days of life; however, the risk-to-benefit ratio of these medications is ill-defined and benzodiazepine medications have not been compared to placebo. OBJECTIVE: To compare the effect of scheduled haloperidol, lorazepam, haloperidol plus lorazepam, and placebo on patients with advanced cancer and delirium and experiencing restlessness and/or agitation in the palliative care setting. DESIGN, SETTINGS, AND PARTICIPANTS: This multicenter randomized clinical trial was conducted at 3 acute palliative care units in Taiwan and the US with patients with advanced cancer experiencing persistent restlessness and/or agitation despite nonpharmacologic therapies and standard-dose haloperidol. Among 245 eligible patients, 111 were enrolled, and 75 received blinded treatments. Participants were randomized in a 1:1:1:1 ratio (stratified by site and Richmond Agitation-Sedation Scale [RASS] score). The study period was from July 16, 2019, to June 8, 2023, with a 30-day follow-up after medication administration. Data analysis was performed from October 10, 2023, to April 11, 2025. INTERVENTIONS: Scheduled intravenous haloperidol, lorazepam, haloperidol plus lorazepam, or placebo every 4 hours until discharge, death, or withdrawal from study. Medications in all 4 groups had identical volume and appearance. MAIN OUTCOMES AND MEASURES: Change in RASS scores during the first 24 hours. Secondary outcomes included the use of rescue neuroleptics or benzodiazepines for breakthrough restlessness or agitation during the first 24 hours, delirium severity, perceived patient comfort, and adverse events. RESULTS: The primary outcome was assessed in 72 patients (mean [SD] age, 64 [12] years, 42 male [58%]) with a median (IQR) MDAS score of 24 (18-29). The lorazepam group had significantly lower RASS scores than the haloperidol group (mean difference, -2.1; 95% CI, -3.4 to -0.9; P < .001) and the combination group had significantly lower RASS scores than the haloperidol group (-2.0; 95% CI, -3.2 to -0.8; P = .002); however, there was no difference observed between haloperidol and placebo groups (-0.5; 95% CI, -1.7 to 0.7; P = .42) nor between the combination and lorazepam groups (0.2; 95% CI, -1.1 to 1.4; P = .79). The combination and lorazepam groups required fewer rescue medications for breakthrough restlessness or agitation compared to the haloperidol and placebo groups (32%, 37%, 56%, 83%, respectively; P = .006). Adverse events or survival did not differ between groups. CONCLUSIONS AND RELEVANCE: The results of this randomized clinical trial indicate that proactive use of scheduled sedatives, particularly lorazepam-based regimens, may reduce persistent restlessness and/or agitation in patients with advanced cancer and delirium in the palliative care setting. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT03743649.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Hui D, De La Rosa A, Tsai JS, et al. Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical Trial. JAMA Oncol. 2025. PMID: 40742738. doi:10.1001/jamaoncol.2025.2212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。